Roswell Park Clinical Trial Points Toward Promising New Therapy for Most Aggressive Type of Breast Cancer
Roswell Park Clinical Trial Points Toward Promising New Therapy for Most Aggressive Type of Breast Cancer
Details
More Products & Services
People
Kimberly Sweeney
Roswell Park Comprehensive Cancer Center
Vice President of Patient Experience
Sai Yendamuri
Roswell Park Comprehensive Cancer Center
Chief Strategy Officer; SVP of Business Development & Outreach; Chair of Thoracic Surgery
Shashi Lele
Roswell Park Comprehensive Cancer Center
Medical Director, International Patients
Sunita Panesar
Roswell Park Comprehensive Cancer Center
Vice President of Strategy, Business Development & Outreach
Description
HIGHLIGHTS:
- Triple-negative breast cancer accounts for 10-20% of all breast cancers
- Study assessed a new pre-surgery immunotherapy/chemotherapy combination
- Findings appear in Journal for ImmunoTherapy of Cancer
- Triple-negative breast cancer accounts for 10-20% of all breast cancers
- Study assessed a new pre-surgery immunotherapy/chemotherapy combination
- Findings appear in Journal for ImmunoTherapy of Cancer
Share
Recent Chats
Share via email
Future: handle WhatsApp here
Future: handle LinkedIn here
Future: handle Twitter here
SUBMENU HERE
Share via Chat
Copy Link